Novel approaches to locally advanced unresectable non-small cell lung cancer

Radiotherapy and Oncology

Volumn 55, Issue 1, 2000, Pages 11-18

  Stevens, Craig W ^a   Lee, Jin Soo ^a   Cox, James ^a   Komaki, Ritsuko ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Chemotherapy; Lung carcinoma; Radiation; Review

Indexed keywords

CISPLATIN; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; ETOPOSIDE; GEMCITABINE; IRINOTECAN; NAVELBINE; PACLITAXEL; PROTEIN FARNESYLTRANSFERASE INHIBITOR; TAXANE DERIVATIVE; TIRAPAZAMINE; TOPOTECAN; VINBLASTINE; VINDESINE;

ADVANCED CANCER; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; GENE THERAPY; HUMAN; LUNG NON SMALL CELL CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; RADIOSENSITIZATION; REVIEW; SURVIVAL RATE; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS; CLINICAL TRIALS, PHASE III; COMBINED MODALITY THERAPY; GENE THERAPY; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; PROGNOSIS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0034175738     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-8140(00)00163-8     Document Type: Review

References (78)

1. Aghajanian C., Brown C., O'Flaherty C., et al. Phase I study of tirapazamine and cisplatin in patients with recurrent cervical cancer. Gynecol. Oncol. 67:1997;127-130.
2. Albain K.S., Rusch V.W., Crowley J.J., et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J. Clin. Oncol. 13:1995;1880-1892.
3. Armstrong J.G. Target volume definition for three-dimensional conformal radiation therapy of lung cancer. Br. J. Radiol. 71:1998;587-594.
4. Bassett D.E. Jr, Eisen M.B., Boguski M.S. Gene expression informatics - it's all in your mine. Nat. Genet. 21:1999;51-55.
5. Belani C.P., Aisner J., Day R., et al. Weekly paclitaxel and carboplatin with simultaneous thoracic radiotherapy (TRT) for locally advanced non-small cell lung cancer (NSCLC): 3 year follow-up. Proc. Am. Soc. Clin. Oncol. 16:1997;448a.
6. Bernhard E.J., Kao G., Cox A.D., et al. The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts. Cancer Res. 56:1996;1727-1730.
7. Bramson J.L., Hitt M., Addison C.L., Muller W.J., Gauldie J., Graham F.L. Direct intratumoral injection of an adenovirus expressing interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin-12. Hum. Gene Ther. 7:1996;1995-2002.
8. Brizel D.M., Scully S.P., Harrelson J.M., et al. Radiation therapy and hyperthermia improve the oxygenation of human soft tissue sarcomas. Cancer Res. 56:1996;5347-5350.
9. Brown J.M. SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumors. Br. J. Cancer. 67:1993;1163-1170.
10. Brown J.M. Exploiting tumor hypoxia and overcoming mutant p53 with tirapazamine. Br. J. Cancer. 77:1998;12-14.
11. Bush D.A., Dunbar R.D., Bonnet R., Slater J.D., Cheek G.A., Slater J.M. Pulmonary injury from proton and conventional radiotherapy as revealed by CT. Am. J. Roentgen. 172:1999;735-739.
12. Chen L.M., Ignacio L., Jacobs R., et al. Results of a phase II concurrent chemoradiotherapy study using three-dimensional conformal radiotherapy with cisplatin and oral etoposide in stage III non-small-cell lung cancer. Radiat. Oncol. Invest. 7:1999;49-53.
13. Choy H., Akerley W., Safran H., et al. Multi-institutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer. J. Clin. Oncol. 16:1998;3316-3322.
14. Choy H., DeVore R.F., Porter L.L., et al. Phase I trial of outpatient weekly docetaxel (DTX) carboplatin (CBDCA) and concurrent thoracic radiation therapy (TRT) for stage III unresectable non-small-cell lung cancer: a Vanderbilt Cancer Center affiliate network (VCCAN) trial. Proc. Am. Soc. Clin. Oncol. 18:1999;475a.
15. Cole K.A., Drizman D.B., Emmert-Buck M.R. The genetics of cancer - a 3D model. Nat. Genet. 21:1999;38-41.
16. Curran W., Scott C., Langer C., et al. Phase III comparison of sequential vs. concurrent chemo-radiation of pts with unresected stage III non-small cell lung cancer (NSCLC): initial report of Radiation Therapy Oncology Group (RTOG) 9410. Proc. Am. Soc. Clin. Oncol. J. Clin. Oncol. 2000;19. (Abstract 1891).
17. Derycke S., Van Duyse B., De Gersem W., De Wagter C., De Neve W. Non-coplanar beam intensity modulation allows large dose escalation in stage III lung cancer. Radiother. Oncol. 45:1997;253-261.
18. Dillman R.O., Herndon J., Seagren S.L., Eaton W.L. Jr, Green M.R. Improved survival in stage III non-small-cell lung cancer: 7-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J. Natl. Cancer Inst. 88:1996;1210-1215.
19. Dorie M.J., Brown J.M. Modification of the antitumor activity of chemotherapeutic drugs by the hypoxic cytotoxic agent tirapazamine. Cancer Chemother. Pharmacol. 39:1997;361-366.
20. Dranoff G., Jaffee E., Lazenby A., et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA. 90:1993;3539-3543.
21. Dubinett S.M., Miller P.W., Sharma S., Batra R.K. Gene therapy for lung cancer. Hematol. Oncol. Clin. N. Am. 1:1998;569-594.
22. Duggan D.J., Bittner M., Chen Y., Meltser P., Trent J.M. Expression profiling using cDNA microarrays. Nat. Genet. 21:1999;15-19.
23. Evans S.M., Bergeron M., Ferriero D.M., et al. Imaging hypoxia in diseased tissues. Adv. Exp. Med. Biol. 428:1997;595-603.
24. Fukuda M., Fukuda M., Soda H., et al. Phase I study of irinotecan (CPT-11) and cisplatin (CDDP) with concurrent thoracic radiotherapy (TRT) in locally advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 18:1999;466a.
25. Furuse K., Fukuoka M., Kawahara M., et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine and cisplatin in unresectable stage III non-small-cell lung cancer. J. Clin. Oncol. 17:1999;2692-2699.
26. Gatzemeier U., Rodriguez G., Treat J., et al. Tirapazamine-cisplatin: the synergy. Br. J. Cancer. 77:1998;15-17.
27. Graeber T.G., Osmanian C., Jacks T., et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature. 379:1996;88-91.
28. Graham M.V., Purdy J.A., Emami B., Matthews J.W., Harms W.B. Preliminary results of a prospective trial using three-dimensional radiotherapy for lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 33:1995;993-1000.
29. Graham M.V., Jain N.L., Kahn M.G., Drzymala R.E., Purdy J.A. Evaluation of an objective plan-evaluation model in the three-dimensional treatment of non-small cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 34:1996;469-474.
30. Henschke C.I., McCauley D.I., Yankelevitz D.F., et al. Early lung cancer action project: overall design and findings from baseline screening. Lancet. 354:1999;99-105.
31. Hospers G.A., Eisenhauer E.A., de Vries E.G. The sulfhydryl containing compounds WR-2721 and glutathione as radio- and chemoprotective agents. A review, indications for use and prospects. Br. J. Cancer. 80:1999;629-638.
32. Ito H., Komaki R., Milas L. Protection by WR-2721 against radiation plus cisdiamminedichloroplatinum II caused injury to colonic epithelium in mice. Int. J. Radiat. Oncol. Biol. Phys. 28:1994;899-903.
33. Komaki R., Scott C., Ettinger D., et al. Randomized study of chemotherapy/radiation therapy combinations for favorable patients with locally advanced inoperable non-small cell lung cancer: Radiation Therapy Oncology Group (RTOG 92-04). Int. J. Radiat. Oncol. Biol. Phys. 38:1997;149-155.
34. Komaki R., Scott C.B., Sause W.T., et al. Induction cisplatin/vinblastine and irradiation vs. irradiation in unresectable squamous clung cancer: failure patterns by cell type in RTOG 88-08/ECOG 4588. Int. J. Radiat. Oncol. Biol. Phys. 39:1997;537-544.
35. Krengli M., Liebsch N.J., Hug E.B., Orecchia R. Review of current protocols for proton therapy in USA. Tumori. 84:1998;209-216.
36. Kutlu C.A., Pastorino U., Maisey M., Goldstraw P. Selective use of PET scan in the preoperative staging of NSCLC. Lung Cancer. 21:1998;177-184.
37. Langer C.J., Movsas B., Hudes R., et al. Induction paclitaxel and carboplatin followed by concurrent chemoradiotherapy in patients with unresectable, locally advanced non-small cell lung carcinoma: report of Fox Chase Cancer Center study 94-001. Semin. Oncol. 24:1997;89-95.
38. Le Chevalier T., Brisgand D., Douillard J.Y., et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multi-center trial including 612 patients. J. Clin. Oncol. 12:1994;360-367.
39. Lee J.D., Ginsberg R.J. The multimodality treatment of stage III A/B non-small cell lung cancer. The role of surgery, radiation, and chemotherapy. Hematol. Oncol. Clin. N. Am. 11:1997;279-301.
40. Lee J.S., Scott C., Komaki R., et al. Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small-cell lung cancer: Radiation Therapy Oncology Group protocol 91-06. J. Clin. Oncol. 14:1996;1055-1064.
41. Maity A., Kao G.D., Muschel R.J., McKenna W.G. Potential molecular targets for manipulating the radiation response. Int. J. Radiat. Oncol. Biol. Phys. 37:1997;739-753.
42. Milas L., Hunter N., Stephens L.C., Peters L.J. Inhibition of radiation carcinogenesis in mice by S-2-(3-Aminopropylamino)-ethylphosphorotioic acid. Cancer Res. 44:1992;5567-5569.
43. Moasser M.M., Sepp-Lorenzino L., Kohl N.E., et al. Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones. Proc. Natl. Acad. Sci. USA. 95:1998;1369-1374.
44. Mountain C.F. A new international staging system for lung cancer. Chest. 89:1989;225S-233S.
45. Mountain C.F. Revisions in the international system for staging lung cancer. Chest. 111:1997;1710-1717.
46. 18F]-deoxyglucose positron emission tomography (FDG-PET) for the planning of radiotherapy in lung cancer: high impact in patients with atelectasis. Int. J. Radiat. Oncol. Biol. Phys. 44:1999;593-597.
47. Perez C.A., Bauer M., Edelstein S., Gillespie B.W., Birch R. Impact of tumor control on survival in carcinoma of the lung treated with irradiation. Int. J. Radiat. Oncol. Biol. Phys. 12:1986;539-547.
48. 18F]fluorodeoxyglucose in the evaluation of pulmonary nodules. Br. J. Surg. 85:1998;1506-1511.
49. Pritchard R.S., Anthony S.P. Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small-cell lung cancer. A meta-analysis. Ann. Intern. Med. 125:1996;723-729.
50. Rak J., Kerbel R.S. Treating cancer by inhibiting angiogenesis: new hopes and potential pitfalls. Cancer Metast. Rev. 15:1996;231-236.
51. Raleigh J.A., Chou S.C., Arteel G.E., Horsman M.R. Comparisons among pimonidazole binding, oxygen electrode measurements, and radiation response in C3H mouse tumors. Radiat. Res. 151:1999;580-589.
52. Ramanathan R.K., Belani C.P. Chemotherapy for advanced non-small cell lung cancer: past, present, and future. Semin. Oncol. 24:1997;440-454.
53. Robertson J.M., Ten Haken R.K., Hazuka M.B., et al. Dose escalation for non-small cell lung cancer using conformal radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 37:1997;1079-1085.
54. Rosell R., Li S., Skacel Z., et al. Prognostic impact of mutated K-ras gene in surgically resected non-small cell lung cancer patients. Oncogene. 8:1993;2407-2412.
55. Roth J.A. Modification of mutant K-ras gene expression in non-small cell lung cancer (NSCLC). Hum. Gene Ther. 7:1996;875-889.
56. Roth J.A., Nguyen D., Lawrence D.D., et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat. Med. 2:1996;985-991.
57. Roth J.A., Swisher S.G., Merrit J.A., et al. Gene therapy for non-small cell lung cancer: a preliminary report of a phase I trail of adenoviral p53 gene replacement. Semin. Oncol. 25:1998;33-37.
58. Sandler A., Nemunaitis J., Dehnam C., et al. Phase III study of cisplatin (C) with or without gemcitabine (G) in patients with advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 17:1998;454a.
59. Satoh H., Okumura T., Yamashita Y.T., Akine Y., Hazegawa S. Proton irradiation for non-small cell lung cancer. Arch. Intern. Med. 158:1998;1379-1380.
60. Sause W.T., Scott C., Taylor S., et al. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J. Natl. Cancer Inst. 87:1995;198-205.
61. ® (Gemcitabine) with thoracic radiotherapy - a phase II pilot study in chemonaive patients with advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 17:1998;499a.
62. Schaake-Koning C., van den Bogaert W., Dalesio O., et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N. Engl. J. Med. 326:1992;524-530.
63. Schiepers C., Hoh C.K. Positron emission tomography as a diagnostic tool in oncology. Eur. Radiol. 8:1998;1481-1494.
64. Scott C., Sause W.T., Byhardt R., et al. Recursive partitioning analysis of 1592 patients on four Radiation Therapy Oncology Group studies in inoperable non-small cell lung cancer. Lung Cancer. 17:1997;S59-S74.
65. Sebti S., Hamilton A.D. Inhibitors of prenyl transferases. Curr. Opin. Oncol. 9:1997;557-561.
66. Siemann D.W., Hinchman C.A. Potentiation of cisplatin activity by the bioreductive agent tirapazamine. Radiother. Oncol. 47:1998;215-220.
67. Steel G.G. The search for therapeutic gain in the combination of radiotherapy and chemotherapy. Radiother. Oncol. 11:1988;31-53.
68. Stolina M., Sharma S., Huang M., et al. Tumor cyclooxygenase-dependent modulation of lymphocyte IL-10 production in murine lung cancer. Proc. Am. Assoc. Cancer Res. 38:1997;A807.
69. Tannehill S.P., Mehta M.P., Larson M. Effect of amifostine on toxicities associated with sequential chemotherapy and radiation therapy for unresectable non-small-cell lung cancer: results of a phase II trial. J. Clin. Oncol. 15:1997;2850-2857.
70. Tenabe K.K. Cancer gene therapy. Surg. Oncol. Clin. N. Am. 7:1998;421-626.
71. Tepper R.I., Mule J.J. Experimental and clinical studies of cytokine gene-modified tumor cells. Hum. Gene Ther. 5:1994;153-164.
72. Uematsu M., Shioda A., Tahara K., et al. Focal, high dose, and fractionated modified stereotactic radiation therapy for lung carcinoma patients: a preliminary experience. Cancer. 82:1998;1062-1070.
73. Von der Maase H. Experimental studies on interactions of radiation and cancer chemotherapeutic drugs in normal tissues and a solid tumour. Radiother. Oncol. 7:1986;47-68.
74. Vokes E.E., Leopold K.A., Herndon J.E. II, et al. A randomized phase II study of gemcitabine or paclitaxel or vinorelbine with cisplatin as induction chemotherapy (Ind CT) and concomitant chemoradiotherapy (XRT) for unresectable stage III non-small cell lung cancer (NSCLC) (CALGB study 9431). Proc. Am. Soc. Clin. Oncol. 18:1999;459a.
75. Weder W., Schmid R.A., Bruchhaus H., Hillinger S., von Schulthess G.K., Steinert H.C. Detection of extrathoracic metastases by positron emission tomography in lung cancer. Ann. Thorac. Surg. 66:1998;886-892.
76. Wozniak A.J., Crowley J.J., Balcerzak S.P., et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J. Clin. Oncol. 16:1998;2459-2465.
77. Zinner R., Fossella F.V., Komaki R. Phase I trial of concurrent gemcitabine (G) plus chest radiotherapy (XRT), followed by consolidation systemic chemotherapy with G plus cisplatin (CDDP), for patients with stage III and medically inoperable stage II non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 18:1999;466a.
78. Zou Y., Zong G., Ling Y.H., et al. Effective treatment of early endobronchial cancer with regional administration of liposome-p53 complexes. J. Natl. Cancer Inst. 90:1998;1130-1137.